Does Doxazosin treatment reduce the nightmares of Post Traumatic Stress Disorder?

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: Not specified

Inclusion Criteria

Age between 18 and 60 years (adults); Clinical diagnosis of PTSD by DSM 5 criteria; Using the first-line drug for the treatment of PTSD; Score equal to or greater than 2 (moderately”), in item B2 (Recurrent distressing dreams) of the Brazilian version of the CAPS-5 scale (PTSD scale administered by the clinician).

Exclusion Criteria

Current or past diagnosis of Manic Episode, Hypomanic Episode or Psychotic Disorder (Schizophrenia, Schizoaffective, etc.); Current homicide risk (according to clinical evaluation); Current moderate to severe suicide risk (as assessed by the MINI instrument); Dependence Diagnosis \ Alcohol or Substance Abuse (except caffeine or nicotine) in the last 12 months using the MINI instrument; Diagnosis of acute or chronic clinical disease with risk of instability throughout the study (unstable angina, acute myocardial infarction in the last 6 months, congestive heart failure, chronic renal failure, liver failure, with Hepatitis B or Hepatitis C) .; Clinical diagnosis of severe neurological disease or dementia; Clinical diagnosis of Benign Paroxysmal Postural Vertigo and its differential diagnoses .; Clinical diagnosis of HIV \ AIDS symptomatic or in use of antiretroviral therapy; Pregnancy, lactation or refusal to initiate \ maintain effective contraceptive method .; Systolic Blood Pressure <110 or Postural Hypotension; Initial electrocardiogram indicating clinically significant change in heart rate. ; Transaminases above twice the upper limit of normal; Current use of alpha-1 blockers (Terazosin, Prazosin) or history of inadequate outcome in treatment with this class of drugs for nightmares associated with PTSD; History of severe adverse reaction associated with the use of alpha-1 blockers (major allergic reaction, priapism, angioedema, ophthalmic disorder); Current use of alpha-2 agonists (clonidine, methyldopa, thiazine, guanfacine); Current use of conivaptan, boceprevir, idelalisib, oral antifungals, alfuzosin, pazopanib, silodosin, or tamulosin; Current use of benzodiazepines; Psychotherapy started in the two months prior to the beginning of the study; Refusal not to use Sildenafil, Tadalafil or Vardenafil during the study